SCHEDULE: Velan Capital Increases Edesa Biotech Stake

Velan Capital Investment Management LP and its affiliates have increased their beneficial ownership in Edesa Biotech, Inc. to 9.99% following a recent public offering.

Summary

• Velan Capital Investment Management LP and its affiliated entities have disclosed an increase in their beneficial ownership of Edesa Biotech, Inc. common shares.
• The reporting persons, including Velan Capital Master Fund LP, Velan Horizon Fund LP, and Velan Capital Opportunity Fund II LLC, collectively hold 1,356,455 shares, representing approximately 9.99% of the outstanding shares.
• This increase is largely due to participation in an underwritten public offering on August 21, 2026, where Velan Master purchased 445,100 shares and warrants, and Velan Horizon purchased 9,445 shares and warrants.
• The total purchase price for Velan Master in the offering was $2,448,050, and for Velan Horizon was $51,948.
• The reporting persons acquired shares and warrants with working capital, which may include margin loans.
• There are limitations on the exercise of new warrants, preventing beneficial ownership exceeding 9.99% of outstanding shares, with the ability to adjust this limit with prior notice.
• Each new warrant is exercisable for one share at $7.50 per share and expires 18 months after issuance or 30 days after Edesa Biotech announces Phase 2 vitiligo topline data for EB06, whichever is earlier.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting increased ownership and participation in a recent offering, but with significant limitations on warrant exercise.

Positives

• Velan Capital has increased its stake in Edesa Biotech, signaling continued confidence or strategic interest.
• The reporting persons participated in a public offering, acquiring a significant number of shares and warrants.
• The aggregate beneficial ownership has reached 9.99%, a notable threshold for an investment fund.

Negatives

• The exercise of new warrants is subject to a strict 9.99% ownership limitation, capping potential future upside from these warrants.
• The expiration of warrants is tied to specific clinical trial data (Phase 2 vitiligo topline data for EB06), introducing an element of uncertainty regarding their ultimate value.

Risks

• The exercise of new warrants is capped at 9.99% of the outstanding shares, limiting the potential for further significant ownership increases through these instruments.
• The expiration of the new warrants is contingent on the announcement of Phase 2 vitiligo topline data for EB06, meaning their value is directly linked to the success of this specific clinical program.
• The reporting persons may increase or decrease the beneficial ownership limitation upon 61 days' prior notice, indicating potential for future strategic shifts.

Future Outlook

The future outlook for the reporting persons' stake is influenced by the exercise of new warrants, which is capped by a 9.99% ownership limitation and tied to the clinical development of EB06. The warrants expire 18 months after issuance or 30 days after the announcement of Phase 2 vitiligo topline data for EB06.

Management Comments

• The filing does not contain direct quotes from management, but rather disclosures regarding beneficial ownership and transactions.
• The reporting persons disclaim beneficial ownership of securities they do not directly own.

Industry Context

StockSavvy.ai notes that activist investor filings like this Schedule 13D often precede or coincide with periods of increased scrutiny or strategic engagement with the issuer. The focus on a specific clinical program (EB06) suggests an investment thesis tied to the company's drug development pipeline.

Comparison to Industry Standards

• The 9.99% ownership threshold is a common reporting trigger for significant investors under SEC regulations.
• The structure of warrants with exercise price and expiration tied to clinical trial milestones is a standard practice in biotechnology financing, though the specific data dependency introduces unique risk/reward dynamics.

Stakeholder Impact

• Shareholders may see increased market activity and potential volatility due to the significant stake held by Velan Capital.
• The exercise limitations on warrants could influence future share price dynamics and dilution concerns.

Next Steps

• Velan Capital may exercise its warrants, subject to the 9.99% ownership limitation.
• The expiration of warrants is contingent on the announcement of Phase 2 vitiligo topline data for EB06.
• Velan Capital may provide 61 days' prior notice to the Issuer to increase or decrease its beneficial ownership limitation.

Key Dates

Recommendation

The filing indicates increased ownership by a significant investment fund, which is generally positive. However, the substantial limitations on warrant exercise and the dependence on specific clinical trial outcomes for warrant value introduce uncertainty. Therefore, a 'hold' recommendation is appropriate pending further developments in Edesa Biotech's clinical programs and the potential exercise of these warrants.

Keywords

Edesa Biotech, Velan Capital, Schedule 13D, Beneficial Ownership, Public Offering, Warrants, Investment Management, Securities